Elaprase(idursulfase)
Elaprase (idursulfase) is an enzyme pharmaceutical. Idursulfase was first approved as Elaprase on 2006-07-24. It is used to treat mucopolysaccharidosis II in the USA. It has been approved in Europe to treat mucopolysaccharidosis II.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Elaprase
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| elaprase | Biologic Licensing Application | 2025-02-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| mucopolysaccharidosis ii | — | D016532 | E76.1 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
idursulfase, Elaprase, Takeda Pharmaceuticals U.S.A., Inc. | |||
| 2113-07-24 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1743 | Injection, idursulfase, 1 mg |
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mucopolysaccharidosis ii | D016532 | — | E76.1 | — | 1 | 1 | 2 | 1 | 4 |
| Syndrome | D013577 | — | — | — | 1 | 1 | 2 | 1 | 4 |
| Mucopolysaccharidoses | D009083 | — | E76.3 | — | — | — | 2 | — | 2 |
| Mucopolysaccharidosis i | D008059 | — | E76.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Idursulfase |
| INN | idursulfase |
| Description | Idursulfase (brand name Elaprase), manufactured by Takeda, is a drug used to treat Hunter syndrome (also called MPS-II). It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.
|
| Classification | Enzyme |
| Drug class | enzymes |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | 5FQL, 6IOZ |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201826 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB01271 |
| UNII ID | 5W8JGG2651 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 794 documents
View more details
Safety
Black-box Warning
Black-box warning for: Elaprase
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,374 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use